Top data from ADA: SGLT2s, prescription fish oil, bempedoic acid address comorbidities

Healio and Endocrine Today have compiled a list of the most read news from the virtual American Diabetes Association Scientific Sessions.

Readers were most interested in the potential of dapagliflozin to reduce risk for diabetes among users with heart failure. Also of interest were studies about managing kidney, liver and cardiovascular diseases among people with diabetes.

Read more below:

DAPA-HF: Dapagliflozin reduces new-onset diabetes among adults with heart failure

Adults with heart failure assigned the SGLT2 inhibitor dapagliflozin had a 32% lower risk for new-onset type 2 diabetes over 18 months of follow-up vs. placebo, according to a planned analysis of DAPA-HF trial data. Read more.

Aggressive management in stage 3 CKD preserves kidney function in diabetes

Adults with type 2 diabetes and a low estimated glomerular filtration rate must be more aggressively managed with tailored treatment options to preserve kidney function and reduce morbidity and mortality risk. Read more.

Undiagnosed liver disease common among US adults with type 2 diabetes

Among U.S. adults with type 2 diabetes attending primary care and endocrinology clinics, less than 40% of those found to have liver fibrosis had elevated aspartate aminotransferase and alanine aminotransferase, according to study data. Read more.

TEDDY data: Early type 1 diabetes signals, environmental triggers and diet associations

Analyses from the ongoing TEDDY study suggest that islet autoimmunity develops by age 2 years for many children who go on to develop type 1 diabetes, and certain illnesses, gut microbiota and even diet may affect disease progression. Read more.

REDUCE-IT DIABETES: Icosapent ethyl lowers CV event risk in type 2 diabetes

Prescription fish oil therapy provides robust cardiovascular benefits in statin-treated adults with type 2 diabetes, with large relative and absolute risk reductions in first and total CV events. Read more.

Bempedoic acid lowers LDL regardless of glycemic status

Researchers found that bempedoic acid significantly reduced LDL compared with placebo in patients with diabetes, prediabetes or normoglycemia and hypercholesterolemia. Read more.

Flash glucose monitoring nearly halves DKA rates in type 1, type 2 diabetes

Among users of a flash glucose monitoring system, rates of diabetic ketoacidosis dropped by 52% for those with type 1 diabetes and by 47% for those with type 2 diabetes, according to data from the RELIEF study. Read more.

SEARCH: HbA1c rising for youths with diabetes despite technology, new therapies

A substantial percentage of youths and young adults with diabetes in the U.S. are not achieving recommended glycemic outcomes despite newer therapies and greater availability of diabetes technology, according to SEARCH study data. Read more.

Novel insulin sensor under development for point-of-care testing, insulin-delivery devices

A wearable microneedle, multifluidic insulin-sensing device may one day allow closed-loop insulin-delivery systems to directly test insulin levels, which in turn might help increase time in range for people with type 1 diabetes. Read more.

EMPRISE: Empagliflozin demonstrates CV safety, efficacy in real-world population

Two interim analyses of the EMPRISE study supported the effectiveness and CV safety of the SGLT2 inhibitor empagliflozin in real-world patients compared with DPP-IV inhibitors and GLP-1 receptor agonists. Read more.